Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792601847> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2792601847 endingPage "iii4" @default.
- W2792601847 startingPage "iii4" @default.
- W2792601847 abstract "Background: While immune checkpoint inhibitors (ICI) are efficacious and lead to durable responses in patients with various cancers, only a minority of patients respond. An approach to increase the efficacy of ICI is to combine them with chemotherapy, in order to enhance immunogenic cell death and “prime” the immune system. However, chemotherapy itself can cause damage to various cell types of the immune system, potentially diminishing the activity of the ICI combination. Using trilaciclib, a short-acting IV CDK4/6 inhibitor that preserves hematopoietic stem cells and enhances immune system function during chemotherapy, we have developed a novel approach to preserve immune system function during chemotherapy to allow optimal activity of ICI. Methods: To evaluate the efficacy of trilaciclib added to chemotherapy/ICI combinations, tumor-bearing immunocompetent mice (MC38 or CT26) were treated with trilaciclib, chemotherapy (oxaliplatin or 5-FU), or ICIs (anti-PD-L1 or anti-PD-1) alone or in combination, and tumor size was measured for up to 100 days. To gain insight into the effect of transient exposure of trilaciclib on the tumor microenvironment, we are examining the cellular composition, proliferation status and gene expression of tumor immune infiltrates from MC38 tumor-bearing mice post-treatment. Results: The addition of trilaciclib to chemotherapy/ICI significantly improved anti-tumor activity and prolonged overall survival. Potential mechanisms by which transient trilaciclib exposure enhances anti-tumor activity include: reduction of Treg populations, preservation of T lymphocyte function, and changes in gene expression leading to enhanced lymphocyte activation and a pro-inflammatory tumor microenvironment. Conclusions: These findings suggest that transient trilaciclib-induced G1 cell-cycle arrest in tumor immune infiltrates prior to chemotherapy/ICI combination treatment creates a favorable tumor microenvironment resulting in increased antitumor activity. Based on these findings, a Phase 2 study to assess the safety and efficacy of trilaciclib or placebo with carboplatin, etoposide, and atezolizumab in first-line extensive stage SCLC patients is ongoing (NCT03041311). Legal entity responsible for the study: G1 Therapeutics Funding: G1 Therapeutics Disclosure: P.J. Roberts, A.Y. Lai, J.A. Sorrentino, R.K. Malik: All authors are employees of G1 Therapeutics." @default.
- W2792601847 created "2018-03-29" @default.
- W2792601847 creator A5039387757 @default.
- W2792601847 creator A5041123635 @default.
- W2792601847 creator A5043074491 @default.
- W2792601847 creator A5068329521 @default.
- W2792601847 date "2018-03-01" @default.
- W2792601847 modified "2023-10-18" @default.
- W2792601847 title "Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models" @default.
- W2792601847 doi "https://doi.org/10.1093/annonc/mdy046.013" @default.
- W2792601847 hasPublicationYear "2018" @default.
- W2792601847 type Work @default.
- W2792601847 sameAs 2792601847 @default.
- W2792601847 citedByCount "2" @default.
- W2792601847 countsByYear W27926018472018 @default.
- W2792601847 countsByYear W27926018472021 @default.
- W2792601847 crossrefType "journal-article" @default.
- W2792601847 hasAuthorship W2792601847A5039387757 @default.
- W2792601847 hasAuthorship W2792601847A5041123635 @default.
- W2792601847 hasAuthorship W2792601847A5043074491 @default.
- W2792601847 hasAuthorship W2792601847A5068329521 @default.
- W2792601847 hasBestOaLocation W27926018471 @default.
- W2792601847 hasConcept C109159458 @default.
- W2792601847 hasConcept C121608353 @default.
- W2792601847 hasConcept C126322002 @default.
- W2792601847 hasConcept C203014093 @default.
- W2792601847 hasConcept C2776107976 @default.
- W2792601847 hasConcept C2776694085 @default.
- W2792601847 hasConcept C2777701055 @default.
- W2792601847 hasConcept C2777761686 @default.
- W2792601847 hasConcept C2780851360 @default.
- W2792601847 hasConcept C28328180 @default.
- W2792601847 hasConcept C502942594 @default.
- W2792601847 hasConcept C54355233 @default.
- W2792601847 hasConcept C71924100 @default.
- W2792601847 hasConcept C86803240 @default.
- W2792601847 hasConcept C8891405 @default.
- W2792601847 hasConceptScore W2792601847C109159458 @default.
- W2792601847 hasConceptScore W2792601847C121608353 @default.
- W2792601847 hasConceptScore W2792601847C126322002 @default.
- W2792601847 hasConceptScore W2792601847C203014093 @default.
- W2792601847 hasConceptScore W2792601847C2776107976 @default.
- W2792601847 hasConceptScore W2792601847C2776694085 @default.
- W2792601847 hasConceptScore W2792601847C2777701055 @default.
- W2792601847 hasConceptScore W2792601847C2777761686 @default.
- W2792601847 hasConceptScore W2792601847C2780851360 @default.
- W2792601847 hasConceptScore W2792601847C28328180 @default.
- W2792601847 hasConceptScore W2792601847C502942594 @default.
- W2792601847 hasConceptScore W2792601847C54355233 @default.
- W2792601847 hasConceptScore W2792601847C71924100 @default.
- W2792601847 hasConceptScore W2792601847C86803240 @default.
- W2792601847 hasConceptScore W2792601847C8891405 @default.
- W2792601847 hasLocation W27926018471 @default.
- W2792601847 hasOpenAccess W2792601847 @default.
- W2792601847 hasPrimaryLocation W27926018471 @default.
- W2792601847 hasRelatedWork W3029687374 @default.
- W2792601847 hasRelatedWork W3108853735 @default.
- W2792601847 hasRelatedWork W3134152892 @default.
- W2792601847 hasRelatedWork W3153709335 @default.
- W2792601847 hasRelatedWork W3177607563 @default.
- W2792601847 hasRelatedWork W3217412908 @default.
- W2792601847 hasRelatedWork W4206354376 @default.
- W2792601847 hasRelatedWork W4224222365 @default.
- W2792601847 hasRelatedWork W4281389645 @default.
- W2792601847 hasRelatedWork W4285731353 @default.
- W2792601847 hasVolume "29" @default.
- W2792601847 isParatext "false" @default.
- W2792601847 isRetracted "false" @default.
- W2792601847 magId "2792601847" @default.
- W2792601847 workType "article" @default.